Literature DB >> 32694806

GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9.

Fernanda Dana Mantelmacher1, Isabel Zvibel1, Keren Cohen1, Alona Epshtein1, Metsada Pasmanik-Chor2, Thomas Vogl3, Yael Kuperman4, Shai Weiss1, Daniel J Drucker5, Chen Varol1,6, Sigal Fishman7.   

Abstract

Enteroendocrine cells relay energy-derived signals to immune cells to signal states of nutrient abundance and control immunometabolism. Emerging data suggest that the gut-derived nutrient-induced incretin glucose-dependent insulinotropic polypeptide (GIP) operates at the interface of metabolism and inflammation. Here we show that high-fat diet (HFD)-fed mice with immune cell-targeted GIP receptor (GIPR) deficiency exhibit greater weight gain, insulin resistance, hepatic steatosis and significant myelopoiesis concomitantly with impaired energy expenditure and inguinal white adipose tissue (WAT) beiging. Expression of the S100 calcium-binding protein S100A8 was increased in the WAT of mice with immune cell-targeted GIPR deficiency and co-deletion of GIPR and the heterodimer S100A8/A9 in immune cells ameliorated the aggravated metabolic and inflammatory phenotype following a HFD. Specific GIPR deletion in myeloid cells identified this lineage as the target of GIP effects. Furthermore, GIP directly downregulated S100A8 expression in adipose tissue macrophages. Collectively, our results identify a myeloid-GIPR-S100A8/A9 signalling axis coupling nutrient signals to the control of inflammation and adaptive thermogenesis.

Entities:  

Keywords:  GIP Receptor (GIPR); Ingwer; Myelopoiesis; S100A4 Expression; Uncoupling Protein (UCP1)

Mesh:

Substances:

Year:  2018        PMID: 32694806     DOI: 10.1038/s42255-018-0001-z

Source DB:  PubMed          Journal:  Nat Metab        ISSN: 2522-5812


  7 in total

1.  Gut Hormone GIP Induces Inflammation and Insulin Resistance in the Hypothalamus.

Authors:  Yukiko Fu; Kentaro Kaneko; Hsiao-Yun Lin; Qianxing Mo; Yong Xu; Takayoshi Suganami; Peter Ravn; Makoto Fukuda
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

2.  GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue.

Authors:  Jonathan E Campbell; Jacqueline L Beaudry; Berit Svendsen; Laurie L Baggio; Andrew N Gordon; John R Ussher; Chi Kin Wong; Fiona M Gribble; David A D'Alessio; Frank Reimann; Daniel J Drucker
Journal:  Diabetes       Date:  2022-05-01       Impact factor: 9.337

3.  GIPR Signaling in Immune Cells Maintains Metabolically Beneficial Type 2 Immune Responses in the White Fat From Obese Mice.

Authors:  Irina Efimova; Inbar Steinberg; Isabel Zvibel; Anat Neumann; Dana Fernanda Mantelmacher; Daniel J Drucker; Sigal Fishman; Chen Varol
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 4.  Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.

Authors:  Jonathan E Campbell
Journal:  Mol Metab       Date:  2020-12-05       Impact factor: 7.422

Review 5.  Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.

Authors:  Qiming Tan; Seun E Akindehin; Camila E Orsso; Richelle C Waldner; Richard D DiMarchi; Timo D Müller; Andrea M Haqq
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-01       Impact factor: 5.555

6.  Saponins from Camellia sinensis Seeds Stimulate GIP Secretion in Mice and STC-1 Cells via SGLT1 and TGR5.

Authors:  Huanqing Zhu; Kaixi Wang; Shuna Chen; Jiaxin Kang; Na Guo; Hongbo Chen; Junsheng Liu; Yuanyuan Wu; Puming He; Youying Tu; Bo Li
Journal:  Nutrients       Date:  2022-08-19       Impact factor: 6.706

Review 7.  Immune-based therapies in cardiovascular and metabolic diseases: past, present and future.

Authors:  Andrew J Murphy; Mark A Febbraio
Journal:  Nat Rev Immunol       Date:  2021-07-20       Impact factor: 53.106

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.